The U.S. biotechnology sector is an indispensable, strategic national asset. But what if we’re taking it for granted? Recent attempts to weaken IP protections for Covid-19 vaccines and to implement drug price controls threaten future U.S. leadership in biotechnology.

The way that hospitals benefit from inflated list prices is a common theme across different kinds of drugs dispensed at hospitals and clinics across the country. When drug prices are a Trojan Horse for all kinds of other health care costs, we all lose.

The difference between investing in space exploration and investing in the biotech industry is about who bears the cost: society as a whole or people as individuals.

Repatriating the American drug supply is key not just to averting shortages but to restoring and preserving the integrity of generic drugs in America.

ICER released a report concluding that Vertex’s groundbreaking triple-combination cystic fibrosis (CF) drug, Trikafta, is too expensive for the value it provides to patients. But is it?

Whatever therapy or intervention solves a previously unmet need is inherently novel. So any treatments for COVID-19 that turn out to work will be "novel" in every way that matters.